Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Génétique des Maladies du Développement, |
RCV000770782 | SCV000902247 | likely pathogenic | Generalized epilepsy with febrile seizures plus, type 2 | 2019-05-03 | criteria provided, single submitter | clinical testing | Familial segregation |
Génétique des Maladies du Développement, |
RCV001004769 | SCV001164249 | uncertain significance | Severe myoclonic epilepsy in infancy | 2018-04-04 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001216747 | SCV001388559 | uncertain significance | Early infantile epileptic encephalopathy with suppression bursts | 2019-04-16 | criteria provided, single submitter | clinical testing | Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be disruptive, but these predictions have not been confirmed by published functional studies and their clinical significance is uncertain. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. This variant has not been reported in the literature in individuals with SCN1A-related conditions. This variant is not present in population databases (ExAC no frequency). This sequence change replaces methionine with threonine at codon 1689 of the SCN1A protein (p.Met1689Thr). The methionine residue is highly conserved and there is a moderate physicochemical difference between methionine and threonine. |
Zotz- |
RCV001004769 | SCV004171561 | likely pathogenic | Severe myoclonic epilepsy in infancy | 2023-11-24 | no assertion criteria provided | clinical testing |